WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS). The main pathogenetic stage of ACS is intracoronary thrombosis, which develops on the s...
Saved in:
| Main Authors: | M. Yu. Gilyarov, Е. V. Konstantinova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-05-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1660 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01) -
The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01) -
P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01) -
Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)